Abstract: A method includes receiving, by a first computing system, a first package of electrocardiogram (ECG) data and metadata associated with the ECG data. The method further includes generating, by the first computing system, a report simulation page including strips of the ECG data and a summary of patient data based on the ECG data and the metadata. The method further includes displaying the report simulation page in a user interface (UI) and displaying a report build page in the UI. The report build page includes the ECG data and the metadata. The method further includes modifying the metadata in the report build page and automatically updating the report simulation page in response to the modifying the metadata.

Abstract: A method includes receiving, by a first computing system, a first package of electrocardiogram (ECG) data and metadata associated with the ECG data. The method further includes generating, by the first computing system, a report simulation page including strips of the ECG data and a summary of patient data based on the ECG data and the metadata. The method further includes displaying the report simulation page in a user interface (UI) and displaying a report build page in the UI. The report build page includes the ECG data and the metadata. The method further includes modifying the metadata in the report build page and automatically updating the report simulation page in response to the modifying the metadata.

Abstract: A method includes receiving, by a first computing system, a first package of electrocardiogram (ECG) data and metadata associated with the ECG data. The method further includes generating, by the first computing system, a report simulation page including strips of the ECG data and a summary of patient data based on the ECG data and the metadata. The method further includes displaying the report simulation page in a user interface (UI) and displaying a report build page in the UI. The report build page includes the ECG data and the metadata. The method further includes modifying the metadata in the report build page and automatically updating the report simulation page in response to the modifying the metadata.

Abstract: A door assembly for a vehicle. The door assembly includes a door frame, a door panel, a rotating strut, and a linear door guide. The door opens and closes through a combination of rotating and sliding motion, which minimizes the required operational footprint. The strut is mounted on the door panel such that the strut is hidden from view when the door is in an open position.

Abstract: A door assembly for a vehicle. The door assembly includes a door frame, a door panel, a rotating strut, and a linear door guide. The door opens and closes through a combination of rotating and sliding motion, which minimizes the required operational footprint. The strut is mounted on the door panel such that the strut is hidden from view when the door is in an open position.

Abstract: An arrangement for fastening a body to a surface, the body having a bore defined there through, includes, but is not limited to, a fitting configured for attachment to the surface. The fitting has a first flange and a second flange spaced apart from the first flange. The first flange has a first opening and the second flange has a second opening substantially axially aligned with the first opening. The arrangement further includes a retaining pin configured to extend through the first opening, the bore, and the second opening when a portion of the body is positioned between the first flange and the second flange. The arrangement further includes a cover member configured to be fastened to the first flange and to obstruct outward movement of the retaining pin from the first opening, the bore, and the second opening when the cover member is fastened to the first flange.

Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.

Abstract: Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R1 and R2 are detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.

Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.

Abstract: The present invention is directed to the preparation of novel compounds useful in the treatment of hyperlipidemia, arteriosclerosis, hypercholesterolemia, and other related metabolic disorders.

Abstract: The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3?(glycogen synthase kinase-3?).

Abstract: A method and system for determining an increased probability of injury to a person. The method and system includes determining at least one factor indicative of a propensity to anatomical failure, determining a probability of an anatomical failure occurring as a function of the at least one factor, the anatomical failure being correlated to an injury, and predicting an increased probability of anatomical failure about to occur as a function of the determined probability, the at least one factor, and a period of time of a condition.

Abstract: The present invention relates to compounds comprising the following formula: R0-Q-X-Q?-W—U—V-G-M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Abstract: The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor Vila is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.

Abstract: The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.

Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.

Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.

Abstract: The present invention relates to compounds of the formula I wherein R0, R1, R2, R3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.